The US Food and Drug Administration has determined that RAVICTI is safe and effective in adult and pediatric patients with UCDs.1
RAVICTI® (glycerol phenylbutyrate) Oral Liquid has a unique mechanism of action designed for a slow release of phenylbutyrate (PBA)1,3-5
An alternate vehicle for waste nitrogen removal can help control ammonia, which can fluctuate daily above the upper limit of normal in patients with urea cycle disorders (UCDs).1,3,4
The absorption of phenylbutyrate is approximately 70% to 75% slower when administered as RAVICTI vs sodium phenylbutyrate.1,5
References: 1. RAVICTI [package insert]. Lake Forest, IL: Horizon Pharma USA, Inc.; 2019. 2. Data on file. Horizon Pharma USA, Inc.; 2015. 3. Lee B, Diaz GA, Rhead W, et al. Genet Med. 2015;17(7):561-568. doi:10.1038/gim.2014.148. 4. Lichter-Konecki U, Diaz GA, Merritt JL II, et al. Mol Genet Metab. 2011;103(4):323-329. doi:10.1016/j.ymgme.2011.04.013. 5. Monteleone JPR, Mokhtarani M, Diaz GA, et al. J Clin Pharmacol. 2013;53(7):699-710. doi:10.1002/jcph.92. 6. The Physician’s Guide to Urea Cycle Disorders. National Organization for Rare Disorders website. 2012. http://nordphysicianguides.org/urea-cycle-disorders/. Accessed May 3, 2017. 7. Braissant O, McLin VA, Cudalbu C. Inherit Metab Dis. 2013;36(4):595-612. doi:10.1007/s10545-012-9546-2. 8. Mokhtarani M, Diaz GA, Rhead W, et al. Mol Genet Metab. 2013;110(4):446-453. doi:10.1016/j.ymgme.2013.09.017. 9. Mokhtarani M, Diaz GA, Rhead W, et al. Mol Genet Metab. 2012;107(3):308-314. doi:10.1016/j.ymgme.2012.08.006. 10. Diaz GA, Krivitzky LS, Mokhtarani M, et al. Hepatology. 2013;57(6):2171-2179. doi:10.1002/hep.26058.
Get everything you need to know about starting, switching, and refining treatment with RAVICTI.
Stay informed about RAVICTI® (glycerol phenylbutyrate) Oral Liquid
Sign up to get the latest information that can help guide your patient management decisions. Fields marked with an asterisk are required.